ESMO Events 2025
ESMO Targeted Anticancer Therapies Asia Congress 2025
ESMO TAT, the multi-stakeholder forum gathering key actors in cancer drug development, arrives in one of the most dynamic and best-connected hubs in Asia, making the latest advances in early clinical trials accessible to everyone in the region. Through in-depth discussions on critical topics such as innovation, digital transformation, research methodology, business insights, regulation, and public policy, ESMO TAT Asia aims to drive progress in cancer treatment and research.
Located in the lively city of Hong Kong, ESMO TAT Asia promises to be a vibrant gathering with region’s industry, academia, clinicians, and regulators to promote international cooperation and accelerate the anticancer research.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma R. Bartolini, L. Trueb, D. Daoudlarian, V. Joo, A. Noto, R. Stadelmann, B. Gentner, C. Fenwick, M. Perreau, G. Coukos, G. Pantaleo, C. Arber, M. Obeid
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma P. Grover, S.N. Lo, I. Li, A.M.J. Kuijpers, F. Kreidieh, A. Williamson, T. Amaral, F. Dimitriou, J. Placzke, K. Olino, M.G. Vitale, P. Saiag, R. Gutzmer, C. Allayous, R. Olofsson Bagge, J. Mattsson, N. Asher, T.J. Carter, T.M. Meniawy, A.R. Lawless, J.A. Czapla, L. Warburton, C. Gaudy-Marqueste, J.J. Grob, R.G. Collins, E. Zhang, J.I. Kessels, B. Neyns, I. Mehmi, O. Hamid, M. Julve, A.J.S. Furness, K.A. Margolin, Shaked Lev-Ari, J.M. Ressler, W. Haque, M.A. Khattak, A. Wicky, R. Roberts-Thomson, A. Arance, G. Warrier, M.D. Schollenberger, P. Parente, E. Chatziioannou, E.J. Lipson, O. Michielin, J.S. Weber, C. Hoeller, J. Larkin, M.B. Atkins, R. Essner, D.B. Johnson, R.J. Sullivan, P. Nathan, J. Schachter, C. Lebbe, P.A. Ascierto, H. Kluger, P. Rutkowski, R. Dummer, C. Garbe, P.C. Lorigan, E. Burton, H.A. Tawbi, J. Haanen, M.S. Carlino, A.M. Menzies, G.V. Long
ESMO Open
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma S. Sato, S.L. Rhodes, Y. Aoki, I. Nakayama, T. Hashimoto, J. Hawkins, R.E. Yanes, C.-H. Chang, Y. Nakamura, A. Kawazoe, S. Mishima, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, S. Yoshino, S. Reading, H. Honeycutt, E. Finger, I. Endo, N. Sakamoto, T. Kuwata, T. Yoshino, K. Shitara
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial D. Ciardiello, L. Boscolo Bielo, F. Pietrantonio, G. Martini, T. Troiani, E. Martinelli, S. Natangelo, M.F. Bosco, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, M. Messina, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A.A. Cogoni, S. Leo, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, F. De Vita, F. Ciardiello, S. Napolitano
Immuno-Oncology and Technology
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE) I.M. Chen, S. Theile, K. Madsen, J.S. Johansen, T. Lorentzen, A. Toxværd, E. Høgdall, I.M. Svane, D. Nielsen
Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: Current approaches and future perspectives Ulisse Salazar, Pauline Cioffi, Betül Taskoparan, Ignacio Moraga, Suman Mitra, Johannes vom Berg
ESMO Gastrointestinal Oncology
Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma M. Tamba, K. Chin, H. Osumi, M. Ogura, S. Fukuoka, S. Udagawa, K. Shimozaki, K. Yoshino, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, A. Ooki
GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial R.C. Grant, K. Duan, R. Jackson, W. Greenhalf, E. Costello-Goldring, P. Ghaneh, C. Halloran, D. Palmer, T. Hackert, M. Büchler, S. Hutchinson, S. Ramotar, A. Dodd, J. Wilson, F. Notta, G. O’Kane, J. Knox, J. Neoptolemos, S. Gallinger, S.E. Fischer
ESMO Real World Data and Digital Oncology
Effectiveness, toxicity and treatment adjustments of lenvatinib plus pembrolizumab in advanced renal cell carcinoma: a multicenter real-world analysis R. Stelmach, S. Erdmann, K. Schlack, C. Muehle, C. Darr, S. Neuberger, M. Reichert, L. Flegar, T. Egenolf, M. Rehlinghaus, F. Zengerling, J. Casuscelli, A. Cox, S. Vallet, T. Nestler, B. Brehmer, P. Ivanyi, P. Paffenholz, M. Neuberger, D. Jäger, V. Grünwald, S. Zschäbitz
Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study A. Miyazaki, K. Kunimasa, T. Morishima, M. Tamiya, T. Inoue, T. Kawamura, T. Tanaka, K. Komuta, S. Futamura, K. Nishino, I. Miyashiro
ESMO Rare Cancers
Mirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors M.A. Akbarzadeh, Y. Vaez-Gharamaleki, M.-S. Hosseini
ESMO affiliated journals
Real-world palbociclib dose modifications and clinical outcomes in patients with HR+/HER2− metastatic breast cancer: A Flatiron Health database analysis Rachel M. Layman, Xianchen Liu, Benjamin Li, Lynn McRoy, Adam Brufsky
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026) Maeve A. Hennessy, Ashley Cimino-Mathews, Jodi M. Carter, Jennifer M. Kachergus, Yaohua Ma, Jeffrey P. Leal, Lilja B. Solnes, Vandana G. Abramson, Lisa A. Carey, Mothaffar Rimawi, Jennifer Specht, Anna Maria Storniolo, Christos Vaklavas, Ian Krop, Eric Winer, Rita Denbow, Vincente Valero, Antonio C. Wolff, Richard L. Wahl, Chiung-Yu Huang, Vered Stearns, E. Aubrey Thompson, Roisin M. Connolly
Paving the path ForwARd: Advances and challenges in androgen receptor targeting in breast cancer Nithya Sridhar, Toshiaki Iwase, Xuemei Xie, Jangsoon Lee, Senthil Damodaran, Naoto T. Ueno Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis Joseph R. Habib, Asad Saulat Fatimi, Omar Mahmud, Ingmar F. Rompen, Benedict Kinny-Köster, Lois A. Daamen, Jin He, I. Quintus Molenaar, Marco Del Chiaro, Christopher L. Wolfgang, Ammar A. Javed, Marc G. Besselink, for the PANC-PALS Consortium
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, Se-Hoon Lee, Pongwut Danchaivijitr, Ying Cheng, Baogang Liu, Adlinda Alip, Hailin Xiong, Soon Hin How, Gee-Chen Chang, James Chih-Hsin Yang, Hiroshige Yoshioka, Mehmet Ali Nahit Şendur, Kumar Prabhash, Koichi Azuma, Yun-Gyoo Lee, Chien-Chung Lin, Shingo Matsumoto, Patrapim Sunpaweravong, Yichuan Xia, Melissa Martinez, Joshua M. Bauml, Seema Sethi, Shun Lu
Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial Matthias Guckenberger, Isabelle Opitz, Tereza Dellaporta, Alessandra Curioni-Fontecedro, Thomas Frauenfelder, Karin Ribi, Ferdinando Cerciello, Ivana Sullivan, Lizza Hendriks, Miriam Dorta, Ana Callejo, Joachim Aerts, Alfredo Addeo, Anne-Marie C. Dingemans, Giulia Pasello, Mariano Provencio, Filippo de Marinis, Nuria Mederos-Alfonso, Heidi Roschitzki-Voser, Barbara Ruepp, Martina Haberecker, Roswitha Kammler, Urania Dafni, Solange Peters, Rolf Stahel, on behalf of the ETOP 14-18 CHESS collaborators
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies Michal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, Benoit Tessoulin, Alexey Danilov, Alvaro J. Alencar, Nirav N. Shah, Hervé Ghesquieres, Steven Le Gouill, Wojciech Jurczak, Hongmei Han, Eunice Yuen, Vishalkumar Patel, Yingying Guo-Avrutin, James M. Pauff, Lindsey E. Roeker
Moving Towards the Delivery of Outpatient T-Cell Engaging Therapy for the Management of Multiple Myeloma Maya Rosenberg, Lauren Scarpetti, Gareth J. Morgan, Faith E. Davies
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.
